English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 5 January 2022, 17:10 HKT/SGT
Share:
    

Source: TrialWire
B-cell lymphoma clinical trials now open on the TrialWire Platform

ADELAIDE, AUS, Jan 5, 2022 - (ACN Newswire) - TrialWire(TM) is pleased to announce new B-cell lymphoma clinical studies are now available on the TrialWire Platform.


More than 6 million people have used TrialWire over the past few years to find clinical trials that are right for them at clinics and specialist centers near them.

The studies on TrialWire are available in Australia, New Zealand, and the U.S. They include new therapies in research for relapsed B-cell lymphoma run by leading lymphoma specialists.

You can search for a study near you and find your local specialist team here. https://www.research-finder.com/b-cell-lymphoma-pr/ Then see if you are eligible and apply instantly.

TrialWire is the most secure and accessible digital clinical trial search platform which is powered by HIPAA compliant Salesforce Health Cloud.

People can search for a clinical trial, check their eligibility and apply instantly. The Platform connects people with Study Coordinators at clinics so they can discuss their condition and eligibility and potentially join a study that is right for them.

Importantly, patient information is only shared with the clinic selected by the applicant. It is not shared, sold or reused to enroll patients in other studies.

TrialWire uses advanced algorithms and AI-Match to find people online who are interested in specific medical conditions. These people have proven to be highly motivated for both enrollment and retention. The biggest challenge to finding cures for medical conditions is that people who might benefit, don't know there is a trial on near them that could be right for them.

Most clinical trials either fail to enroll enough patients or need to extend enrollment timelines adding significant time and cost.

TrialWire provides a rapid and secure enrolment solution that benefits patients and sponsors.

TrialWire Platform sources clinical trial information from leading Government databases of approved clinical trials.

Find B-cell lymphoma clinical trial near you today. Places for most clinical trials are limited. Clinical trials can offer advanced check-ups, advice and care as well as access to the latest therapies in research. https://www.research-finder.com/b-cell-lymphoma-pr/

About TrialWire(TM) www.Trial-Wire.com

TrialWire(TM) is the leading digital patient recruitment platform for Sponsors and CROs requiring a rapid study recruitment boost.

Unlike all other recruitment tools, TrialWire uses advanced algorithms to find people when they are searching for health solutions online and, within 2 minutes, AI-Matches them with studies near them (or for DCTs) and connects them directly with the relevant site.

TrialWire Study Dashboards for Sponsors, CROs and Study Coordinators are powered by Salesforce Health Cloud providing the most secure and informative insights across the entire recruitment process.

Topic: Press release summary
Source: TrialWire

Sectors: BioTech, Healthcare & Pharm, Clinical Trials
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

TrialWire Related News
Apr 11, 2023 08:00 HKT/SGT
TrialWire Patient Recruitment Platform Launches AI Pre-recruit to Cut Recruitment Time by 50%
July 20, 2022 09:00 HKT/SGT
TrialWire Technology Platform Rolls Out World First SMS/Text Patient Contact System Across all Studies Globally
July 18, 2022 15:00 HKT/SGT
TrialWire(TM) 技術平台宣布基於成功的患者招募計劃
July 18, 2022 15:00 HKT/SGT
TrialWire Technology Platform Announces Success-based Patient Recruitment Plan
July 18, 2022 15:00 HKT/SGT
TrialWire(TM) 技术平台宣布基于成功的患者招募计划
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575